in the phase 3 KEYNOTE-590 clinical trial, frontline pembrolizumab plus chemotherapy demonstrated a significant improvement in overall survival, progression-free survival, and objective response rates versus chemotherapy only in patients with locally advanced unresectable or metastatic esophageal cancer, result presented during the 2020 EsMO Virtual Congress show.
Pembrolizumab Plus Chemotherapy Enters Frontline Treatment Landscape of Advanced Esophageal Cancer